UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

Schiffmann, R; Hughes, DA; Linthorst, GE; Ortiz, A; Svarstad, E; Warnock, DG; West, ML; (2017) Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney International , 91 (2) pp. 284-293. 10.1016/j.kint.2016.10.004. Green open access

[thumbnail of Hughes_1-s2.0-S0085253816306032-main.pdf]
Preview
Text
Hughes_1-s2.0-S0085253816306032-main.pdf - Published version

Download (451kB) | Preview

Abstract

Patients with Fabry disease (FD) are at a high risk for developing chronic kidney disease and cardiovascular disease. The availability of specific but costly therapy has elevated the profile of this rare condition. This KDIGO conference addressed controversial areas in the diagnosis, screening, and management of FD, and included enzyme replacement therapy and nonspecific standard-of-care therapy for the various manifestations of FD. Despite marked advances in patient care and improved overall outlook, there is a need to better understand the pathogenesis of this glycosphingolipidosis and to determine the appropriate age to initiate therapy in all types of patients. The need to develop more effective specific therapies was also emphasized.

Type: Article
Title: Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
Open access status: An open access version is available from UCL Discovery
DOI: 10.1016/j.kint.2016.10.004
Publisher version: https://doi.org/10.1016/j.kint.2016.10.004
Language: English
Additional information: © 2016 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/4.0/).
Keywords: Science & Technology, Life Sciences & Biomedicine, Urology & Nephrology, Chronic Kidney Disease, Enzyme Replacement Therapy, Fabry Disease, Fabry Nephropathy, Standard Of Care, Enzyme-Replacement Therapy, Agalsidase-Beta Therapy, Left-Ventricular Hypertrophy, Randomized Controlled-Trial, Nervous-System Involvement, Natural-History Data, Stage Renal-Disease, Neuropathic Pain, Alpha-Galactosidase, Adult Patients
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science > Clinical Science
URI: https://discovery.ucl.ac.uk/id/eprint/1534898
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item